30 天前 - … On day two of nirmatrelvir/ritonavir, her INR rose to 4.0 on home point of care INR …
remained supratherapeutic the day after completing nirmatrelvir/ritonavir (4.0) and for several …

57 天前 - … with COVID-19 four days earlier and treated with Ritonavir and Nirmatrelvir (Paxlovid),
was referred from a nursing facility due to sudden altered mentation and hypotension. …

87 天前 - … No patient was treated with Nirmatrelvir/Ritonavir. 14 patients received 4 units of
CP and 10 patients received 2 units. The one-month survival rate was 81% and the three-…

118 天前 - … antiviral drug nirmatrelvir/ritonavir in nursing home patients with … safety of
nirmatrelvir/ritonavir in nursing home patients … study including all nursing home patients attended …

143 天前 - This Special Issue comprises 14 original studies and 2 reviews, and will serve as a
platform to further the current knowledge of antibody responses against RNA virus infections…

163 天前 - … Receipt of prior stem cell transplantation, COVID-19 vaccination(s), and treatment
with nirmatrelvir/ritonavir or remdesivir were associated with greater survival rates. In …

182 天前 - … Background: Paxlovid (nirmatrelvir/ritonavir) is a novel oral anti-viral therapy for
COVID-… -organ transplant), primary care, and long-term care homes. On average, patients were …

185 天前 - … The medications in use against mild-to-moderate COVID-19 in the outpatient
setting during the study period are nirmatrelvir-ritonavir, remdesivir, molnupiravir, and …

213 天前 - … emergency use authorization (EUA) for nirmatrelvir-ritonavir (Paxlovid). This was
based … We aimed to study the risk factors for seeking medical care following Paxlovid treatment…

300 天前 - … For patients treated in out-patient care with mild or moderate infection of covid-19,
today we have perioral antiviral drugs nirmatrelvir/ritonavir and a molnupiravir. During …